About Nexalin
Nexalin is a company based in Tustin (United States) founded in 2010. Nexalin has raised $501.71 thousand across 1 funding round. The company has 6 employees as of December 31, 2024. Nexalin offers products and services including Nexalin Device. Nexalin operates in a competitive market with competitors including Flow Neuroscience, Freespira, Sooma Oy, HypnoVR and Feel Therapeutics, among others.
- Headquarter Tustin, United States
- Employees 6 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nexalin Technology, Inc.
-
Annual Revenue
$168.72 K (USD)52.35as on Dec 31, 2024
-
Net Profit
-$7.61 M (USD)-63.64as on Dec 31, 2024
-
EBITDA
-$7.74 M (USD)-35.97as on Dec 31, 2024
-
Total Equity Funding
$501.71 K (USD)
in 1 rounds
-
Latest Funding Round
$501.71 K (USD), Seed
Aug 08, 2011
-
Investors
Not available
-
Employee Count
6
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nexalin
Nexalin is a publicly listed company on the NASDAQ with ticker symbol NXL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nexalin
Nexalin offers a comprehensive portfolio of products and services, including Nexalin Device.
Non-invasive waveform treatment for anxiety and insomnia relief.
Funding Insights of Nexalin
Nexalin has successfully raised a total of $501.71K through 1 strategic funding round. The most recent funding activity was a Seed round of $501.71 thousand completed in August 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Nexalin
Investment portfolio details for Nexalin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nexalin
Detailed financials for Nexalin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nexalin Comparisons
Peer comparison for Nexalin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nexalin
Nexalin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flow Neuroscience, Freespira, Sooma Oy, HypnoVR and Feel Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of a wearable device for stress and anxiety management
|
|
| Locked | Locked | Locked |
Panic disorders are treated via breathing device and mobile app.
|
|
| Locked | Locked | Locked |
Non-invasive neuromodulation therapies
|
|
| Locked | Locked | Locked |
Virtual reality therapies for pain and anxiety reduction are developed.
|
|
| Locked | Locked | Locked |
Provider of digital Precision Medicine company leveraging objective data and passive measurement for mental healthcare
|
|
| Locked | Locked | Locked |
Wearable technology is developed for stress reduction and sleep enhancement.
|
Detailed competitors of Nexalin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nexalin
Complete news archive for Nexalin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nexalin
Nexalin was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Nexalin is headquartered in Tustin, United States. It is registered at Tustin, California, United States.
Nexalin is a funded company, having raised a total of $501.71K across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Nexalin is 6.
Annual revenue of Nexalin is $168.72K as on Dec 31, 2024.
Nexalin was founded in 2010 and is headquartered in Tustin, United States. A non-invasive medical device is developed by the company for treating anxiety, depression, and insomnia through a patented frequency-based waveform that targets mid-brain structures to regulate neurochemicals. The therapy has been cleared by the FDA and operates within the mental health sector, focusing on drug-free interventions.
Nexalin's top competitors include NeuroSigma, Flow Neuroscience and Freespira.
Nexalin offers Nexalin Device.
Yes, Nexalin is publicly traded on NASDAQ under the ticker symbol NXL.
The ticker symbol of Nexalin is NXL on NASDAQ.